NAS10031,283+0.66%S&P7,829+0.71%GOLD$4,200+1.03%BTC$85,499−0.34%VIX15.03−3.16%live tape · as of 19:04 UTC
The Screen · Healthcare · Biotechnology
Disc Medicine, Inc.
IRON · Nasdaq · USD · Market cap $2.5B · 154 employees
Disc Medicine, Inc., together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hemato…
FAIL · Does not pass the screen
64.51 USD
Screen close, 2026-10-02 · not a live quote Last reviewed 4 days ago
Screened 2026-10-02 · the tape above runs as of 19:04 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
PRICE · FAIR-VALUE RANGE1M3M6MYTD1Y3Y5Y
What this means: price 64.51 against the desk's fair-value range, base estimate 100.00, over the last year.
Positioning no disclosures inside 60 days, left as found
Options no verdict drawn today, left as found
Ethical does not pass the values gate
Price64.51 USD
Fair value100.00
Ethical score70.0/100
Our investment reviews on this name
2026-10-02Read Markdown68.49-5.8% to today ✓
2026-09-02Read Accumulation82.67-22.0% to today
2026-08-02Read Markup76.15-15.3% to today
2026-07-02Read Accumulation67.99-5.1% to today
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Disc Medicine, Inc. holds its Markdown at $64.51. Consolidating, no directional conviction, held for 50 days.
As held on the ledger · 2026-10-02
Phase
Markdown · caution
Quantitative state
Consolidating, no directional conviction, held for 50 days
Price at the screen
$64.51
Valuation
N/A trailing · -9.11 forward price to earnings
Values screen
FAIL· score 70.0
Beta
2.05
The Workings
Five Screens, Shown in Full
Does not pass. Interest-bearing securities
Test
Figure
Limit
What it means
Status
Business activity
Permissible
Core business clean
Its core business isn't built on prohibited lines: no gambling, alcohol, tobacco, weapons, or interest-based lending.
Pass
Debt load
3.84%
Below 33%
Interest-bearing debt is just 3.8% of its assets, well under the one-third ceiling: it does not run on borrowed money.
Pass
Interest-bearing cash
86.75%
Below 33%
Interest-bearing cash and securities are 86.8% of assets, above the one-third limit.
Fail
Receivables
11.30%
Below 49%
Money owed to the company is 11.3% of assets, under the 49% limit.
Pass
Revenue purity
Excluded
Below 5%
of revenue comes from non-compliant sources, over the 5% line.
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Disc Medicine,'s business is fine, but its cash and interest-bearing securities are about 87% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 2026-10-04. It updates when the underlying figures move, and past reads are kept below.
Fair value range in USD, drawn from the 2026-10-02 screen. The gold marker is the market price at the same screen. A 55.0% margin of safety to the base estimate.
Third-party analyst targets: 12 covering, consensus Strong Buy. The average target sits +55% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-02 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Clinical Biotech Hits Ethics Data Wall
Backing a firm that has yet to turn a profit or ship a product is like funding a research lab on the promise of a breakthrough cure. Disc Medicine is still in early trials for blood disorders, with zero margins, negative returns on equity, and a forward multiple that reflects deep losses rather than earnings power. The ethical screen returns insufficient data, so we pass regardless of analyst targets or any calculated margin of safety.
The business model hinges on future approvals that may never arrive, and the absence of basic financial ratios leaves the usual checks on governance and conduct impossible to complete. Strong buy ratings from the Street do not override that gap.
Risk sits in the usual clinical and regulatory failures plus the added uncertainty of an incomplete ethical review. Analysis, not advice.
The risks · The things to watch: it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
IRON trades on Nasdaq. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-02Markdown · changed$68.49-17.2%Entry 6
The framework has shifted from accumulation to markdown since the last review. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 17.2% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 27%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (11 analysts) rates it none, with a mean price target of $101. Insiders have been net sellers over the past quarter.
The framework has shifted from markup to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 8.6% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 27%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (11 analysts) rates it none, with a mean price target of $101. Insiders have been net sellers over the past quarter.
2026-08-02Markup · changed$76.15+12.0%Entry 4
The framework has shifted from accumulation to markup since the last review. Price is trending higher with momentum. The crowd has caught on and buyers are in control. Price has moved up 12.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 27%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (11 analysts) rates it none, with a mean price target of $101.
2026-07-18Accumulation$67.99+0.0%Entry 3
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 27%. Our forward projection puts the odds of a 10% gain over the next month near 36%. The street (11 analysts) rates it none, with a mean price target of $101.
2026-07-03Accumulation$67.99+0.0%Entry 2
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
2026-07-02Accumulation$67.99Entry 1
The framework reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows good risk-adjusted returns.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
